Connect Biopharma Holdings Limited: Form 6-K Summary
Business Context and Reporting Period
Connect Biopharma Holdings Limited, a foreign private issuer, furnished this Form 6-K for September 2023. The report was signed on September 12, 2023, and concerns a Nasdaq listing compliance notification received on September 11, 2023.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Change
- Nasdaq notified the Company that its American Depositary Shares had closed below the $1.00 minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1).
- The Company received an initial 180-calendar-day compliance period ending March 11, 2024, to regain compliance.
- Compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days during the compliance period.
Outlook, Risks, and Contingencies
- The notification has no immediate effect on the listing or trading of the ADSs, which continue to trade on the Nasdaq Global Market under the symbol CNTB.
- The Company intends to monitor its ADS bid price and consider available options if the price does not recover sufficiently.
- If compliance is not restored by March 11, 2024, the Company may be eligible for an additional 180-day period, subject to transfer to the Nasdaq Capital Market and satisfaction of applicable market value and other initial listing requirements.
- If the Company is not eligible for, or does not appear likely to achieve, compliance, Nasdaq may initiate delisting proceedings. The Company would have appeal rights, but there is no assurance that continued listing would be granted.
Important Facts to Verify
- Whether the ADS closing bid price reaches at least $1.00 for 10 consecutive business days before March 11, 2024.
- Whether Nasdaq confirms regained compliance or grants an additional compliance period.
- Whether a transfer to the Nasdaq Capital Market, reverse split, or other corporate action becomes necessary to address the deficiency.
- Any subsequent Nasdaq delisting notice, appeal, or impact on the ADS listing and trading.